RNAimmune logo
Startup

RNAimmune

See RNAimmune's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2021

Total Funding

$12.4M

Employees

1 - 10

Status

Active


About RNAimmune

We are able to deliver a wider variety of mrnas with enhanced intracellular expression.

Headquarters

United States


General Information on RNAimmune

Brand name RNAimmune
Company name RNAimmune Inc.RN
Website https://www.rnaimmune.com/
Founded year 2021
Employees 1 - 10
Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about RNAimmune

Daily Record 30.03.2022
RNAimmune secures $27M in Series A financing

RNAimmune Inc., a biopharmaceutical company in Gaithersburg specializing in discovery and development of mRNA-based therapeutics and vaccines, announced Wednesday it has secured $27 million in a Series A round of financing. The company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases. The round was led by existing shareholders of ...

RNAimmune news
PR Newswire 30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

GAITHERSBURG, Md., March 30, 2022/ PRNewswire/-- RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US $27 million Series A round of f

RNAimmune news
Menafn.com 30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing fo...| MENAFN.COM

discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing. The Company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases. The round was led by existing shareholders of RNAimmune, including Sirnaomics Ltd. (' Sirnaomics ', stock code: ...

usalifesciences.com 30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines GAITHERSBURG, Md.

Since its establishment in March 2020, RNAimmune has built up its mRNA vaccine and drug discovery and development platform to tackle high unmet medical needs in infectious diseases, cancer and rare diseases. The Company submitted the pre-IND meeting package for its lead candidate, RIM730, an mRNA vaccine for COVID-19 with the U.S. Food and Drug Administration (FDA) in October 2021 and received the green light in January 2022. The Company ...

Bioworld 14.12.2021
Rnaimmune measuring its COVID-19 vaccine candidate’s mettle against Omicron

Rnaimmune Inc., which in April raised a $10 million seed round to support its discovery and development of RNAi therapies, said it is now studying the neutralizing effects of its mRNA-based COVID-19 vaccine candidate on the Omicron variant. “Before Omicron appeared, studies demonstrated that our COVID-19 vaccine showed neutralization against all strains,” Shen Dong, CEO of Rnaimmune, told BioWorld.

RNAimmune news